Cargando…

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting

PURPOSE: Triple therapy comprising a long-acting muscarinic antagonist, long-acting β(2)-agonist and inhaled corticosteroid is recommended for patients with chronic obstructive pulmonary disease (COPD) who continue to experience frequent exacerbations or symptoms whilst receiving dual therapy. Adher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpin, David M G, Rothnie, Kieran J, Banks, Victoria, Czira, Alexandrosz, Compton, Chris, Wood, Robert, Tritton, Theo, Massey, Olivia, Wild, Rosie, Snowise, Neil, Nikitin, Kirill, Sharma, Raj, Ismaila, Afisi S, Vogelmeier, Claus F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519012/ https://www.ncbi.nlm.nih.gov/pubmed/36185170 http://dx.doi.org/10.2147/COPD.S370540

Ejemplares similares

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
por: Rothnie, Kieran J, et al.
Publicado: (2023)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study
por: Rothnie, KJ, et al.
Publicado: (2022)

SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study
por: Ismaila, AS, et al.
Publicado: (2022)

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
por: Sansbury, Leah B, et al.
Publicado: (2022)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice
por: Sansbury, Leah B, et al.
Publicado: (2021)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
por: Bremner, Peter R., et al.
Publicado: (2018)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
por: Neches García, Victoria, et al.
Publicado: (2022)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Comparison of Bayesian and frequentist approaches in modelling risk of preterm birth near the Sydney Tar Ponds, Nova Scotia, Canada
por: Ismaila, Afisi S, et al.
Publicado: (2007)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_lu3u9f4nvjvd32aof215t30hsf